BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 32776743)

  • 1. Study of Circulating Natural Antibodies Against CD25 and FOXP3 in Type-2 Diabetes.
    Qiu C; Li C; Wu X; Chen X; Zhang X; Meng Q
    Clin Lab; 2020 Aug; 66(8):. PubMed ID: 32776743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of Plasma Antibodies Against CD25-Derived Peptide Antigens in Bladder Cancer.
    Du KL; Ji WT; Jiang QH; Wang Y
    Clin Lab; 2023 May; 69(5):. PubMed ID: 37145070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteration of circulating natural autoantibodies to CD25-derived peptide antigens and FOXP3 in non-small cell lung cancer.
    Zhao H; Zhang X; Han Z; Xie W; Yang W; Wei J
    Sci Rep; 2018 Jun; 8(1):9847. PubMed ID: 29959381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further Study of Circulating Antibodies to P16, CD25 and FOXP3 in Hepatocellular Carcinoma.
    Wang J; Xu Y; Wang Y; Zhang X; Zhang G
    Onco Targets Ther; 2019; 12():10487-10493. PubMed ID: 31819529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Change of circulating antibodies against CD25-derived peptide antigen in hepatocellular carcinoma.
    Wang J; Xu Y; Zhao H; Zhang X
    J Cancer Res Ther; 2017; 13(5):813-816. PubMed ID: 29237909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of circulating natural antibodies against CD25, MUC1, and VEGFR1 for early diagnosis of non-small cell lung cancer.
    Liu S; Zhang X; Jiang Q; Liang T
    FEBS Open Bio; 2020 Jul; 10(7):1288-1294. PubMed ID: 32392378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of circulating antibodies against CD25 and FOXP3 in breast cancer.
    Liu T; Song YN; Shi QY; Liu Y; Bai XN; Pang D
    Tumour Biol; 2014 Apr; 35(4):3779-83. PubMed ID: 24347486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study of circulating anti-CD25 antibodies in non-small cell lung cancer.
    Ye L; Li X; Sun S; Guan S; Wang M; Guan X; Lee KH; Wei J; Liu B
    Clin Transl Oncol; 2013 Aug; 15(8):633-7. PubMed ID: 23263913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4
    Peixoto TV; Carrasco S; Botte DAC; Catanozi S; Parra ER; Lima TM; Ugriumov N; Soriano FG; de Mello SBV; Rodrigues CM; Goldenstein-Schainberg C
    Adv Rheumatol; 2019 Jul; 59(1):30. PubMed ID: 31340848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical stoichiometric ratio of CD4(+)  CD25(+)  FoxP3(+) regulatory T cells and CD4(+)  CD25(-) responder T cells influence immunosuppression in patients with B-cell acute lymphoblastic leukaemia.
    Bhattacharya K; Chandra S; Mandal C
    Immunology; 2014 May; 142(1):124-39. PubMed ID: 24354800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes.
    Brusko T; Wasserfall C; McGrail K; Schatz R; Viener HL; Schatz D; Haller M; Rockell J; Gottlieb P; Clare-Salzler M; Atkinson M
    Diabetes; 2007 Mar; 56(3):604-12. PubMed ID: 17327427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of regulatory CD4+CD25+ Foxp3 T cells in bronchial asthma in Egyptian children.
    Bakr SI; Mahran MZ; Soliman DA
    Egypt J Immunol; 2013; 20(2):29-38. PubMed ID: 24617045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of circulating natural antibodies to inflammatory cytokines in type-2 diabetes and clinical significance.
    Cai W; Qiu C; Zhang H; Chen X; Zhang X; Meng Q; Wei J
    J Inflamm (Lond); 2017; 14():24. PubMed ID: 29142506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Th17 and CD4
    Xiang M; Guo L; Ma Y; Li Y
    Pak J Pharm Sci; 2016 Nov; 29(6 Suppl):2405-2410. PubMed ID: 28167485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low frequency of CD4+CD25+ Treg in SLE patients: a heritable trait associated with CTLA4 and TGFbeta gene variants.
    Barreto M; Ferreira RC; Lourenço L; Moraes-Fontes MF; Santos E; Alves M; Carvalho C; Martins B; Andreia R; Viana JF; Vasconcelos C; Mota-Vieira L; Ferreira C; Demengeot J; Vicente AM
    BMC Immunol; 2009 Jan; 10():5. PubMed ID: 19173720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of CD4+CD25+Foxp3+ Regulatory T Cells, Interleukin 10 and Transforming Growth Factor β in Newly Diagnosed Type 2 Diabetic Patients.
    Yuan N; Zhang HF; Wei Q; Wang P; Guo WY
    Exp Clin Endocrinol Diabetes; 2018 Feb; 126(2):96-101. PubMed ID: 28954308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered homeostasis of CD4(+) FoxP3(+) regulatory T-cell subpopulations in systemic lupus erythematosus.
    Suen JL; Li HT; Jong YJ; Chiang BL; Yen JH
    Immunology; 2009 Jun; 127(2):196-205. PubMed ID: 18800986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4
    Polanczyk MJ; Walker E; Haley D; Guerrouahen BS; Akporiaye ET
    J Transl Med; 2019 Jul; 17(1):219. PubMed ID: 31288845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low expressions of PD-L1 and CTLA-4 by induced CD4
    Zhao L; Zhou X; Zhou X; Wang H; Gu L; Ke Y; Zhang M; Ji X; Yang X
    Cytokine; 2020 Sep; 133():155119. PubMed ID: 32535334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo depletion of CD4+CD25+ regulatory T cells in cats.
    Smithberg SR; Fogle JE; Mexas AM; Reckling SK; Lankford SM; Tompkins MB; Dean GA
    J Immunol Methods; 2008 Jan; 329(1-2):81-91. PubMed ID: 17980384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.